Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.38 |
| ▸ | ABAT | P80404 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4582740 | 0.89 | HRH3 (0.48) | SPHK1HRH3LOXL2ABATESR2 | |
| SCHEMBL11997346 | 0.81 | HRH3 (0.44) | SPHK1HRH3LOXL2ABATESR2 | |
| SCHEMBL10232991 | 0.81 | HRH3 (0.44) | SPHK1HRH3LOXL2ABAT | |
| SCHEMBL2837369 | 0.80 | SPHK1 (0.40) | SPHK1HRH3LOXL2ABATESR2 | |
| SCHEMBL7508590 | 0.80 | ESR2 (0.59) | SPHK1HRH3LOXL2ABATESR2 | |
| SCHEMBL7508598 | 0.80 | ESR2 (0.59) | SPHK1HRH3LOXL2ABATESR2 | |
| SCHEMBL5049395 | 0.79 | F2 (0.44) | HRH3LOXL2 | |
| SCHEMBL13660206 | 0.79 | F2 (0.44) | HRH3LOXL2 | |
| SCHEMBL22291710 | 0.79 | F2 (0.44) | HRH3LOXL2 | |
| Hydrochloric Acid SCHEMBL250061 | 0.79 | HRH3 (0.42) | SPHK1HRH3LOXL2ABAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170059-B1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | disclosed |
| US-8436028-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARP & DOHME CORP (US) | 2013-05-07 | — | — | US | disclosed |
| US-20100197630-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC | 2010-08-05 | — | — | US | disclosed |
| EP-2170059-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | Merck Sharp & Dohme Corp. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008156717-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197630-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | CETP, APOB, MTTP | SPHK1 1285/4885HRH3 2488/4885LOXL2 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.